Patent EP0542679A1 successfully refreshed from Google Patents.
EP0542679A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel hybrid transforming growth factors
Assignee: Novartis AG
•
Filing: 1992-11-03
•
Granted: —
•
Expires: 2012-11-03
Abstract
Abstract The invention relates to novel hybrid TGF-βs, a process for the production of biologically active, dimeric hybrid proteins and pharmaceutical compositions comprising them. Hybrid TGF-βs produced by this process can be used in various therapeutic modalities such as for the promotion and acceleration of wound healing and bone and tissue repair, the treatment of cancer, as a bone marrow protective agent, mediator of cardioprotection, anti inflammatory or immunosuppressive agent or as a growth regulator in mammalian cell cultures.
Inventors
- 👤 Gary Kent Dr. Mcmaster
- 👤 David Dr. Cox
- 👤 Nico Dr. Cerletti
- 👤 Jochen Dr. Kuhla
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 15:17
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A; A61; A61P; A61P43/00; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/70; C07K2319/74; C07K2319/75
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
31 words
A hybrid TGF-β molecule consisting of two or more parts, said parts consisting of contiguous stretches of 6 or more amino acids of a sequence which occurs in mature TGF-β isoforms.
Claim 2
Dependent Claim
17 words
A hybrid TGF-β molecule according to claim 1 consisting of 2, 3, 4, 5 or 6 parts.
Claim 3
Dependent Claim
12 words
A hybrid TGF-β molecule according to claim 1 consisting of two parts.
Claim 4
Dependent Claim
38 words
A hybrid TGF-β molecule according to claim 3 consisting of parts of the TGF-β isoforms human TGF-β1, human TGF-β2 and human TGF-β3 with the amino acid sequences depicted the Sequence Listing under SEQ ID NO. 1 to 3.
Claim 5
Dependent Claim
46 words
A hybrid TGF-β molecule according to claim 1 having a hinge point between parts derived from different parent TGF-β isoforms selected from the group of hinge points between amino acids 44 and 45, 56 and 57, 79 and 80, 90 and 91, and 22 and 23.
Claim 6
Dependent Claim
85 words
A hybrid TGF-β molecule according to claim 1 selected from the group consisting of the hybrids consisting of a N-terminal part of TGF-β1 and a C-terminal part of TGF-β2, a N-terminal part of TGF-β2 and a C-terminal part of TGF-β1, a N-terminal part of TGF-β1 and a C-terminal part of TGF-β3, a N-terminal part of TGF-β3 and a C-terminal part of TGF-β1, a N-terminal part of TGF-β2 and a C-terminal part of TGF-β3, and a N-terminal part of TGF-β3 and a C-terminal part of TGF-β2.
Claim 7
Dependent Claim
47 words
A hybrid TGF-β molecule according to claim 1 selected from the group consisting of the hybrids TGF-β1(44/45)β2, TGF-β2(44/45)β1, TGF-β1(44/45)β3, TGF-β3(44/45)β1, TGF-β2(44/45)β3, TGF-β3(44/45)β2, TGF-β1(56/57)β2, TGF-β2(56/57)β1, TGF-β1(56/57)β3, TGF-β3(56/57)β1, TGF-β2(56/57)β3, TGF-β3(56/57)β2, TGF-β1(79/80)β2, TGF-β2(79/80)β1, TGF-β1(79/80)β3, TGF-β3(79/80)β1, TGF-β3(79/80)β2, TGF-β2(79/80)β3, TGF-β1(90/91)β2, TGF-β2(90/91)β1, TGF-β1(90/91)β3, TGF-β3(90/91)β1, TGF-β3(90/91)β2, TGF-β2(90/91)β3, TGF-β1(22/23)β2, TGF-β2(22/23)β1, TGF-β1(22/23)β3, TGF-β3(22/23)β1, TGF-β3(22/23)β2, and TGF-β2(22/23)β3.
Claim 8
Dependent Claim
35 words
A hybrid TGF-β molecule according to claim 1 selected from the group consisting of the hybrids TGF-β1(44/45)β2, TGF-β2(44/45)β1, TGF-β1(44/45)β3, TGF-β3(44/45)β1, and TGF-β2(44/45)β3, TGF-β3(44/45)β2 depicted in the sequence listing under SEQ ID NOs. 4 to 9.
Claim 9
Dependent Claim
21 words
The hybrid TGF-β molecule according to claim 1 which is TGF-β3(44/45)β2 depicted in the sequence listing under SEQ ID NO. 9.
Claim 10
Dependent Claim
13 words
A recombinant DNA molecule encoding a hybrid TGF-β molecule according to claim 1.
Claim 11
Dependent Claim
21 words
A recombinant DNA molecule according to claim 10 which is an expression vector for the preparation of a hybrid TGF-β molecule.
Claim 12
Dependent Claim
13 words
A method for the preparation of a DNA molecule according to claim 10.
Claim 13
Dependent Claim
11 words
A host transformed with a DNA molecule according to claim 10.
Claim 14
Dependent Claim
14 words
A method for the preparation of a hybrid TGF-β molecule according to claim 1.
Claim 15
Dependent Claim
12 words
A pharmaceutical composition comprising a hybrid TGF-β molecule according to claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.